Published in Gene Therapy Weekly, May 18th, 2006
"Approximately 50% of NF1 patients exhibit skeletal pathology, such as premature osteoporosis or pseudoarthroses. Loss of neurofibromin deregulates Ras signal transduction to affect generation of mitogen-activated protein kinase and Akt, both of which have been implicated in parathyroid hormone (PTH) anabolic mechanisms," wrote X. Yu and colleagues, Indiana University.
They continued, "Our aim was to determine if loss of neurofibromin impaired the anabolic effect of PTH on bone mass. Nf1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.